Dabrafenib in the treatment of advanced melanoma.

Advanced melanoma has long been a challenging malignancy to treat due to a relative paucity of efficacious therapeutic options. However, the identification of activating BRAF mutations in approximately 50% of patients with cutaneous melanoma has ushered in the era of targeted therapy for melanoma patients. Similar to the first-in-class selective serine/threonine-protein kinase B-raf inhibitor vemurafenib, dabrafenib is highly efficacious in melanoma patients with BRAF V600E mutations, with response rates of approximately 50% and progression-free survival of 6 months. There is data to suggest that dabrafenib not only shows activity in V600E-mutated melanoma, but also in non-V600E BRAF-mutated disease such as V600K. There is also early data to suggest that dabrafenib is effective in controlling metastases in the brain. Combining dabrafenib with the selective mitogen-activated protein kinase kinase (MEK) inhibitor trametinib has been effective in improving both the progression-free survival and overall survival of melanoma patients over those patients treated with dabrafenib alone. Dabrafenib is still being evaluated in several clinical trials in melanoma as well as a variety of other solid tumors with BRAF mutations. The U.S. Food and Drug Administration has recently approved dabrafenib as a single agent for the treatment of unresectable or metastatic melanoma in adult patients with BRAF V600E mutation.
AuthorsT Medina, M N Amaria, A Jimeno
JournalDrugs of today (Barcelona, Spain : 1998) (Drugs Today (Barc)) Vol. 49 Issue 6 Pg. 377-85 (Jun 2013) ISSN: 1699-3993 [Print] United States
PMID23807941 (Publication Type: Journal Article, Review)
CopyrightCopyright 2013 Prous Science, S.A.U. or its licensors. All rights reserved.
Chemical References
  • Antineoplastic Agents
  • Imidazoles
  • Oximes
  • Proto-Oncogene Proteins B-raf
  • dabrafenib
  • Antineoplastic Agents (therapeutic use)
  • Clinical Trials as Topic
  • Drug Interactions
  • Humans
  • Imidazoles (adverse effects, pharmacology, therapeutic use)
  • Melanoma (drug therapy)
  • Oximes (adverse effects, pharmacology, therapeutic use)
  • Proto-Oncogene Proteins B-raf (antagonists & inhibitors)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: